• The combination of a structurally concentrated supply base, rising geopolitical risk from the dominant Russian supplier, and persistent demand from the automotive sector creates a clear rationale for Western nations to secure alternative sources of palladium.
• The latest news from Greenland Mines confirms that its Skaergaard project just became more valuable.
• The 2026 field season is already underway at Skaergaard, with drilling, bulk sampling for metallurgical test work, geotechnical measurements, engineering studies and environmental baseline all in progress.

Palladium is one of the most strategically important metals on earth, and the supply chain that delivers it to Western manufacturers has never been more exposed. Into that gap steps Greenland Mines (NASDAQ: GRML), which just reported a 31% increase in its indicated palladium equivalent resource at its Skaergaard project in southeast Greenland, one of the largest undeveloped palladium, gold and platinum deposits in the western world.

Most people encounter palladium without knowing it. It sits inside the catalytic converter of nearly every gasoline-powered vehicle on the road, where it converts harmful exhaust gases into less toxic emissions. Automotive applications account for roughly 80% to 85% of total global palladium demand. That makes palladium’s supply chain a direct input into the global auto industry’s ability to function.

The supply picture is what makes palladium strategically sensitive. Russia accounts for approximately 40% of global palladium supply, with the bulk of that coming from Norilsk Nickel’s Arctic operations. South Africa supplies most of the rest. That means three-quarters of the world’s palladium originates in two countries, one of which has become a deeply unreliable trading partner for Western nations.

In 2025, the U.S. International Trade Commission voted to continue investigations into Russian palladium imports after determining there was reasonable indication of material injury to the U.S. industry. The original petition, filed by Sibanye-Stillwater and the United Steelworkers Union, alleged a dumping margin of 828%. The U.S. Department of Commerce issued a final affirmative determination on April 28, 2026, effectively pricing Russian palladium out of the U.S. market.

Global palladium supply has been in deficit since 2012. Annual demand exceeded supply by roughly 5–9% of total consumption in 2023 and 2024. Those deficits have been bridged by drawing down above-ground stockpiles accumulated over decades. Stockpiles do not last forever.

The combination of a structurally concentrated supply base, rising geopolitical risk from the dominant Russian supplier, and persistent demand from the automotive sector creates a clear rationale for Western nations to secure alternative sources. Greenland is politically stable, geographically accessible and sits within allied-nation critical mineral frameworks — one of the few places on earth where a large, undeveloped palladium deposit exists.

That deposit is Skaergaard, and the latest news from Greenland Mines confirms it just became more valuable. On July 15, 2026, the company reported that independent consultant SLR Consulting (Canada) Ltd. had completed the first SEC S-K 1300-compliant Technical Report Summary for the project, incorporating an updated 2026 Mineral Resource Estimate. The results were material across every key metric. Indicated palladium equivalent contained metal increased 31% to 15.0 million ounces. Indicated PdEq grade rose 36% to 3.04 grams per tonne. Inferred contained PdEq metal grew 24% to 17.49 million ounces. Inferred PdEq grade climbed 44% to 3.07 grams per tonne.

Two factors drove the upgrade. The first was updated metal price assumptions, including gold at $3,500 per ounce, which more accurately reflect the current market environment. The second was an improved geological model. SLR’s team replaced the prior panel methodology with an industry-standard block model that better reflects the true bowl-shaped geometry of the Skaergaard deposit. The prior approach had introduced artificial dilution, pushing material below cut-off that now correctly sits above it. The result is, as the company described it, the same rock but more accurately characterized and worth more per tonne mined.

Greenland Mines president Bo Møller Stensgaard put it directly: “We have taken the 2022 mineral resource — already substantial — applied current gold and palladium prices and an improved block model methodology that better reflects the true geometry of the deposit, and the result is a resource that is more than 31% larger in Indicated PdEq ounces with a grade 36% higher. That is a material upgrade in the economic quality of what Skaergaard holds.”

The S-K 1300 conversion is more than a reporting formality. It establishes Skaergaard on a U.S. regulatory foundation and creates the platform from which the company can proceed to an Initial Assessment, the S-K 1300 equivalent of a Preliminary Economic Assessment. A key focus of that assessment will be an open-pit scenario targeting near-surface mineralization on the northern plateau, where gold, palladium and platinum occur at or close to surface. Open-pit operations typically carry lower capital and operating costs than underground mining, a factor that could meaningfully improve the project’s economics and accelerate the timeline to potential production.

The 2026 field season is already underway. Drilling, bulk sampling for metallurgical test work, geotechnical measurements, engineering studies and environmental baseline work are all in progress. Results from this campaign will feed directly into the planned initial assessment. The deposit also contains elevated levels of titanium, vanadium and gallium in the surrounding iron-oxide sequence, representing potential byproduct credits subject to further evaluation.

For more information, visit www.GreenlandMines.com.

NOTE TO INVESTORS: The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML

• Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately 470,000 annual knee cartilage repair procedures and growing demand for regenerative medicine solutions.
• Regentis is advancing GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform designed to simplify treatment, improving patient outcomes while fitting current surgical workflows and supporting durable cartilage repair.
• These developments underscore the company’s broader mission: To establish a new standard of care in cartilage repair through biomaterial-based regenerative technologies.

Regentis Biomaterials (NYSE American: RGNT) is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundreds of thousands of patients each year and contributing to pain, reduced mobility, and degenerative joint disease, the company is targeting one of orthopedic medicine’s largest unmet needs.

GelrinC’s commercial potential is rooted in the combination of clinical differentiation and practical adoption. The product is designed to deliver advanced cartilage repair through a practical, approximately 10-minute, single-step procedure, without cell harvesting, laboratory expansion, patient-specific manufacturing, or a second surgery. At the same time, clinical data generated to date have shown meaningful and durable improvements in pain and function, together with evidence of high-quality cartilage repair tissue. The result is a rare value proposition in orthopedics: a regenerative treatment designed to be clinically differentiated, economically practical, scalable across surgical centers, and capable of supporting faster return to daily activity and work.

Industry Validation Supports the Regenerative Medicine Thesis

The regenerative medicine sector continues to gain regulatory validation. Recent FDA De Novo authorization of TISSIUM’s suture-less tissue repair platform highlights growing acceptance of advanced biomaterials designed to improve healing and simplify procedures. While addressing a different clinical indication, the milestone reflects broader momentum supporting biomaterial-based regenerative technologies such as Regentis’ GelrinC.

GelrinC Targets a Major Unmet Need

Regentis is pursuing this opportunity through GelrinC, its proprietary hydrogel-based implant designed to support the regeneration of damaged knee cartilage through a simple, single-step procedure. Unlike many existing treatment options that require cell harvesting, laboratory processing, and extended recovery periods, GelrinC is designed as an off-the-shelf solution that can be integrated into standard surgical workflows. 

The company’s approach seeks to reduce procedural complexity while promoting durable cartilage regeneration and improved patient outcomes.

A Differentiated Biomaterials Platform

Regentis sits at the convergence of biomaterials engineering, regenerative medicine, and orthopedic innovation. Its proprietary hydrogel implant technology is engineered to support the body’s natural regenerative processes, gradually degrading as hyaline-like cartilage tissue forms.

Clinical data have demonstrated approximately 100% greater pain improvement than microfracture procedures while also showing durable cartilage repair, reinforcing GelrinC’s potential differentiation from both conventional treatments and more complex cell-based therapies.

Significant Commercial Potential

The company’s commercial opportunity is further strengthened by its focus on knee cartilage repair, which represents the largest segment of the cartilage repair market, accounting for approximately 46% of industry revenue. Management estimates the U.S. market opportunity alone exceeds $3 billion annually, providing substantial room for expansion upon regulatory approval and commercial adoption in the United States.

Following CE Mark approval in Europe, Regentis is advancing commercialization through surgeon training, market education, and Centers of Excellence engagement while continuing its Phase III U.S. clinical program.

Multiple Catalysts Underway

With CE Mark approval already secured in Europe and a pivotal Phase III clinical trial underway in the United States, Regentis continues advancing toward a PMA submission with the FDA, providing investors with multiple potential value-driving milestones over the coming years.

Positioned at the Intersection of Innovation and Growth

As regenerative medicine gains broader clinical and regulatory acceptance, Regentis is positioned at the intersection of biomaterials innovation and orthopedic care. With encouraging clinical data, a differentiated platform, and exposure to a multibillion-dollar market opportunity, the company is advancing toward several meaningful commercial and regulatory milestones.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

• Wrap Technologies treats non-lethal response as a system rather than a single device, integrating tools, training, and policy into one Non-Lethal Response(TM) ecosystem for modern public safety.
• Its platform pairs the patented BolaWrap(R) 150 remote response-to-resistance device with Wrap Reality(TM) VR training, Wrap Vision(TM) evidence management, and Wrap Tactics(TM) digital training, reinforced by IADLEST-certified instruction and human-centered policy frameworks.
• In July 2026 the company launched WrapShield(TM), extending that integrated approach from the officer’s belt to an autonomous, AI-enabled platform designed to detect, orchestrate, and respond.

A System, not a Single Device

Law enforcement officers routinely face non-compliant individuals and people in crisis in the narrow interval where verbal commands have not worked but higher levels of force are not yet warranted. Wrap Technologies (NASDAQ: WRAP) builds technology to give officers additional options in that interval, guided by a mission the company describes as helping to save lives through safer outcomes. Rather than selling a standalone tool, Wrap integrates equipment, training, and policy into a single Non-Lethal Response(TM) system so agencies can adopt response-to-resistance capabilities as a complete program.

The company’s solutions have gained meaningful traction, with more than 1,000 law enforcement agencies across 60+ countries deploying Wrap’s technology. Demonstrations continue to expand internationally, including a recent event in Italy, where multiple police agencies have already adopted the company’s solutions.

The Tool: BolaWrap(R) 150

At the center of the platform is the BolaWrap(R) 150, a patented, handheld device that discharges a Kevlar(R) tether to help officers restrain a non-compliant individual from approximately 10 to 25 feet. Wrap describes it as the only remote response-to-resistance tool designed to preserve safe distance between subject and officer without relying on pain compliance. It does not shoot, strike, shock, or incapacitate; instead, it helps officers operate earlier, in the pre-escalation phase of the force continuum. In July 2026, the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives (“ATF”) determined that the BolaWrap(R) 150 is an instrument of restraint rather than a firearm or “any other weapon” under federal law, which the company believes supports remote restraint as a distinct category in modern public safety.

The Training and Policy Layers

Wrap surrounds the device with training and a policy that makes consistent field use possible. Wrap Reality(TM) delivers fully immersive virtual-reality scenarios to build decision-making under stress, while Wrap Tactics(TM) provides policy-aligned digital training and certification that sustains proficiency after classroom instruction ends. Wrap Vision(TM) captures and manages digital evidence to support transparency and accountability. This ecosystem is reinforced by training partnerships with the STORM Training Group and Force Science, and by human-centered, “machine-to-man” policy work with the Law Enforcement Training and Advisory Council (“LETAC”) that keeps human judgment as the ultimate authority.

The Next Evolution: The WrapShield(TM) Platform

Wrap has described WrapShield as the next evolution of the company, connecting advanced sensing, artificial intelligence, command-and-control, and measured response into a unified operating architecture. The company frames this shift around three pillars: validation (the ATF ruling establishing remote restraint as its own category), intelligence (an exclusive U.S. and NATO license to Frenel Imaging’s thermal-polarimetric sensing, adding an AI-enabled detection layer), and integration (WrapShield itself).

WrapShield is designed to connect detection, decision, and response across complex operational environments, detecting threats earlier, classifying them with AI-assisted decision support, and integrating the response technologies a customer trusts. The company describes an architecture of layered operations — detect, identify, classify, direct, respond, and escalate only when authorized — with human decision-makers designed to remain in control. Its initial application is counter-unmanned aircraft systems, with an architecture intended to expand across critical infrastructure, border security, transportation, public venues, corrections, and defense support.

Leadership and Vision

Wrap is led by Founder, Chairman, and CEO Scot Cohen, whose background spans more than two decades in asset management, wealth management, and capital markets, alongside President and Chief Operating Officer Jared Novick. Cohen has framed the company’s direction plainly: the market does not need more disconnected devices, but a unified system that brings together sensing, AI, command-and-control, and graduated, accountable response, beginning with the belt-worn BolaWrap and extending to the WrapShield platform. The company is headquartered in Miami, Florida, with manufacturing operations in Southwestern Virginia as part of a made-in-America supply-chain initiative.

During a recent interview, Cohen explained that the company’s original vision was straightforward: create a non-lethal restraint device that officers could carry on their belts and use to safely take unarmed, non-violent individuals into custody without relying on pain compliance techniques such as pepper spray or conducted energy devices. That mission has since evolved into a broader strategy of providing law enforcement agencies with an integrated ecosystem of technologies and training designed to support safer, more effective policing.

For more information, visit the company’s website at WRAP.com.

NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP

• Safe Pro Group recently announced that it was awarded a Small Business Innovation Research (“SBIR”) contract focused on developing a new AI dataset that will be used in airfield operations.
• Specifically, the dataset will be made using images of debris and damage that are commonly encountered on military and civilian airfields and will help address common challenges that the Department of the Air Force (“DAF”) faces.
• Developing these AI datasets could rapidly expand the applicability of Safe Pro’s computer vision technology and open up a brand-new potential market opportunity in both commercial and defense airfield operations.

Safe Pro Group (NASDAQ: SPAI), a developer of AI-powered security and defense solutions, recently announced that it was awarded a Small Business Innovation Research (“SBIR”) contract by AFWERX, which is the innovation arm of the Department of the Air Force (“DAF”) (https://ibn.fm/Z0jsM).

The contract is focused on developing a new AI dataset using images of Foreign Object Debris/Damage (“FOD”) that are often found on both U.S. Air Force (“USAF”) and civilian airfields, in order to help with the most pressing issues and challenges in the DAF.

The goal of this SBIR program is to fund emerging technologies to deliver Air Force and Space Force capabilities and expand access to disruptive innovation. 

Also, AFWERX has partnered with the Air Force Research Laboratory to streamline the SBIR process by speeding up the small business experience with faster proposal to award timelines, expanding opportunities to small businesses, and getting rid of bureaucratic overhead.

Developing AI datasets for use in U.S. Air Force airfield operations could greatly expand the applicability of Safe Pro’s computer vision technology, which is designed to rapidly detect and identify small and potentially dangerous objects on both the battlefield and in post-conflict zones.

This SBIR award also follows the recent expression of interest by the U.S. Army in this capability, as the Army invited Safe Pro to provide operational support to soldiers during an airfield exercise.

Regarding the award, the Chairman and CEO of Safe Pro, Dan Erdberg, said that “The receipt of this Air Force award represents a significant new potential market opportunity for our novel AI-powered image analysis platform, expanding it into both defense and commercial airfield operations. We look forward to working with the AFWERX team on this exciting new capability and to further expanding our ability to deliver AI-powered solutions for improved situational awareness and operational decision making.”

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that develops and delivers advanced AI-powered defense and security solutions to consumers in various markets including law enforcement, defense, homeland security, and humanitarian. The core of Safe Pro’s mission revolves around computer vision software technology that rapidly identifies and detects small objects in drone images and videos.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• The Pentagon no longer treats jamming and spoofing as a contingency but as a baseline condition of modern conflict.
• Sparc AI approaches that problem from the software side rather than through new hardware, offering its Overwatch platform that delivers precision navigation and target acquisition for drones and autonomous systems.
• The company has also been building the commercial infrastructure to bring that technology to actual defense customers.

Modern militaries-built decades of doctrine on the assumption that satellites would always know where a soldier, drone or missile stood, and that assumption is now breaking down in real time. The Air Force Research Laboratory recently awarded a $49.7 million contract specifically to mature technologies that can operate without GPS, a clear signal that the Pentagon no longer treats jamming and spoofing as a contingency but as a baseline condition of modern conflict. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) has spent years building toward this moment, developing software that lets drones and autonomous systems navigate and acquire targets without GPS, radar, lidar or any external signal at all.

The scale of the disruption behind that Air Force contract is difficult to overstate. GPS satellites broadcast extremely weak signals from roughly 20,200 kilometers up, a structural weakness that adversaries have learned to exploit at scale, and IATA’s 2024 safety report documented approximately 430,000 GPS jamming and spoofing incidents over conflict zones that year, up 62% from 2023. A single jamming event tied to Russia’s Kaliningrad exclave disrupted more than 1,600 aircraft over eastern Europe in a two-day span in March 2024, and a cheap software-defined-radio jammer costing roughly $50 can already disrupt GPS across a localized area.

Similar concerns are being reported by Military.com, which noted that autonomous military systems increasingly cannot rely on GPS at all, whether the signal is jammed, spoofed or simply unavailable underground, underwater or beneath dense foliage. ANELLO Photonics CEO Mario Paniccia told the outlet that any autonomous system being built today needs the ability to operate in a GPS-denied or GPS-spoofed environment, and that jamming and spoofing are already happening rather than looming as future risks. These reports point to a defense establishment now actively funding and fielding alternatives rather than debating whether they are needed.

What both reports make clear is that the fix cannot simply be a better GPS. The signal weakness that enables jamming is a matter of physics, not engineering, which is why the Pentagon is funding multiple parallel tracks, from quantum inertial sensors to new low-earth-orbit satellite constellations to fiber optic gyroscopes, each targeting the same underlying problem from a different angle.

SPARC AI approaches that problem from the software side rather than through new hardware. The company’s Overwatch platform was built to deliver precision navigation and target acquisition for drones and autonomous systems. It’s designed to operate in denied, degraded, intermittent and limited environments. Rather than adding new sensors, it converts the low-cost inertial sensors already built into commercial drones into precision instruments through advanced mathematical modeling.  Because the approach is software only, it can be deployed at the price point and scale that modern drone operations require, from a single platform up to fleets numbering in the thousands.

That design also addresses a second battlefield vulnerability beyond GPS dependence: detectability. SPARC AI’s technology is described as zero signature, meaning it does not rely on radar, lidar or other active emissions that can reveal a platform’s position to an adversary. This is an important distinction from many competing navigation approaches that require their own detectable sensors to function. The company has extended that same software architecture into ATLAS, a mission-planning tool launched in October 2025 that runs visibility and line-of-sight simulations entirely in software, eliminating the need for the active sensing hardware that traditional terrain mapping tools require.

SPARC AI has also been building commercial infrastructure to bring that technology to actual defense customers. In November 2025, the company signed a nonexclusive global reseller agreement with Precision Technic Defence Group, a 40-year-old defense integrator with seven offices spanning Europe, the United States and Australia. This agreement gives Sparc AI a distribution channel into established military procurement relationships across those regions. In February 2026, the company announced a separate reseller partnership to bring its platform into Ukraine, beginning with field testing in what the company describes as the world’s most demanding operational environment for GPS-denied drone warfare.

Placed against the backdrop of the Air Force’s $49.7 million alt-navigation contract and the broader shift in Pentagon assumptions, SPARC AI’s positioning appears ideally timed. The company was pursuing GPS-independent navigation and zero-signature target acquisition before this became a funded federal priority, and the recent reports on battlefield GPS failure only reinforce the scale of the market its Overwatch and ATLAS platforms are built to serve.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

• ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine
• The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs
• Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers

Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific therapies. By matching treatments to the unique biology of a patient’s tumor, physicians can improve outcomes while reducing unnecessary exposure to therapies that may offer limited clinical benefit (ibn.fm/tNpcJ).

Drug developers are increasingly designing therapies for biomarker-defined patient populations, while regulations, clinicians, and healthcare systems continue to expand the use of genomic testing to guide treatment decisions. As precision oncology becomes the new standard of care, developers capable of creating targeted therapies for genetically defined cancers are positioned to address one of oncology’s fastest-growing markets.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is aligning its development strategy with this industry transformation through ONC010, its lead nanoparticle-encapsulated Polynucleotide kinase-phosphatase (“PNKP”) inhibitor. Designed for biomarker-selected cancers, ONC010 targets tumors that may be particularly susceptible to DNA Damage Response (“DDR”) therapies. The program combines a novel therapeutic target with nanoparticle drug delivery and an AI-native discovery platform, positioning Onco-Innovations within one of oncology’s most promising areas of innovation.

As the company advances toward First-in-Human clinical studies, it is building the scientific and manufacturing foundation supporting ONC010. Recent milestones include the initiation of polymer process development and analytical characterization activities with Nanosoft Polymers, designed to establish a robust, scalable, and reproducible manufacturing platform (ibn.fm/ztsui). According to CEOThomas O’Shaughnessy, “The initiation of this work with Nanosoft represents an important step in strengthening the manufacturing and formulation foundation of ONC010.” He noted that the collaboration is helping establish “a more scalable and reproducible pathway toward future GMP manufacturing and clinical development.”

In parallel, Onco-Innovations has initiated three-species hepatocyte and liver microsome metabolism studies through Nucro-Technics, a key component of its integrated IND-enabling development strategy (ibn.fm/0UaW4). These studies are intended to characterize how ONC010 is metabolized across human, dog, and rat systems, generating data capable of supporting pharmacokinetic modeling, dose selection, toxicology planning, and future regulatory submissions. Together with ongoing chemistry, manufacturing and controls (“CMC”) activities, initiatives are designed to reduce development risk while preparing ONC010 for clinical evaluation.

Onco-Innovations operates at the intersection of precision medicine, targeted oncology, advanced drug delivery, and artificial intelligence. Its integrated development ecosystem combines proprietary PNKP inhibitors, nanoparticle formulation technologies, specialized manufacturing expertise, and AI-driven discovery tools to speed up the development of therapies for biomarker-selected cancers.

For more information, visit https://oncoinnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF

• SS Innovations will showcase its SSi Mantra surgical robotic system at the Society of Robotic Surgery (“SRS”) 2026 Annual Meeting in Florida on July 23-26.
• The presentation will feature a live kidney telesurgery broadcast from India, demonstrating the remote capabilities of the SSi Mantra platform.
• Chairman and CEO Dr. Sudhir Srivastava to participate in multiple conference presentations covering telesurgery, robotic surgery adoption and regulatory developments.
• As of July 6, 2026, more than 12,375 procedures have been completed using the SSi Mantra system, including cardiac, pediatric and telesurgical procedures.
• Approximately 2,100 physicians have already been trained on the platform, which has been used across more than 170 different surgical procedures.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, will bring its SSi Mantra surgical robotic system to one of the largest annual gatherings of robotic surgery specialists, highlighting the company’s expanding clinical experience and growing focus on remote surgical capabilities. The company announced that the SSi Mantra will be showcased during the Society of Robotic Surgery (“SRS”) 2026 Annual Meeting, scheduled for July 23-26 in Hollywood, Florida (https://ibn.fm/FkgsY).

The robotic platform will be demonstrated throughout the conference and featured in multiple technical sessions. One of the event’s focal points will be a live robotic telesurgery in which a partial nephrectomy will be performed remotely by Dr. Amitabh Singh from SS Innovations’ headquarters in Gurugram, India, on a patient at Rajeev Gandhi Cancer Institute and Research Centre in New Delhi.

The planned procedure is intended to demonstrate the capabilities of the company’s telesurgery platform in a live educational setting before surgeons, researchers and medical technology professionals attending the conference.

Company Chairman and Chief Executive Officer Dr. Sudhir Srivastava is also scheduled to participate in several presentations and panel discussions covering cardiac telesurgery, robotic surgery adoption, regulatory considerations, global access to robotic care and developments in soft-tissue robotics.

“This influential forum provides us with a prime opportunity to highlight the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency,” Dr. Srivastava said. “During this year’s event, I will (…) continue to share SS Innovations’ mission of democratizing global access to advanced surgical robotic care.”

SS Innovations has continued expanding the clinical use of its SSi Mantra platform during the past year. According to the company, more than 12,375 multi-specialty procedures had been completed using the robotic system as of July 6, 2026. Those cases include 653 cardiac procedures, 178 telesurgeries, and 225 pediatric surgeries.

The company also reports that approximately 2,100 physicians have received training on the SSi Mantra platform, which has been used in more than 170 different surgical procedures across multiple specialties. Those figures reflect continued growth in clinical utilization, an important metric for companies developing surgical robotics because expanding physician adoption typically generates additional experience, procedural data and training opportunities.

The SSi Mantra is designed as a modular robotic surgery platform capable of supporting a broad range of minimally invasive procedures. Its architecture includes three to five robotic arms, an open-console surgeon workstation, three-dimensional 4K visualization, integrated imaging capabilities and a suite of more than 40 robotic surgical instruments supporting specialties that include general surgery, urology, gynecology, cardiac surgery, pediatric surgery and ear, nose and throat procedures.

Among the platform’s distinguishing features is the optional SSi MantrAsana tele-surgeon console, which enables surgeons to perform procedures remotely while maintaining functionality comparable to the standard operating console.

Remote surgery remains an emerging segment within robotic medicine. While regulatory, technical and infrastructure challenges continue to shape its adoption, proponents believe telesurgery could eventually expand access to specialized surgical expertise for patients in underserved regions.

SS Innovations has stated that the SSi Mantra is the only surgical robotic platform to have been used for cardiac telesurgery. Although telesurgery continues to evolve and currently represents a relatively small portion of overall robotic surgery activity, the company views the capability as an important component of its long-term technology strategy.

Beyond remote surgery, SS Innovations continues to position the SSi Mantra as a cost-conscious alternative within the broader robotic surgery market. The company says its objective is to make robotic-assisted procedures more affordable and accessible while supporting hospitals that may face financial barriers to adopting existing robotic systems. That strategy combines technology development with physician training, clinical validation and international expansion.

SS Innovations has steadily increased both the number of installed systems and the range of procedures supported by its platform. Earlier this year, the company announced that the SSi Mantra had surpassed 10,500 cumulative procedures, a figure that has continued to grow as adoption expands.

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• Canamera has commenced exploration at its São Sepé Project in Brazil, where three high-priority rare earth targets have already been identified
• The company is building a diversified Brazilian rare earth portfolio as Western nations seek alternatives to China’s supply dominance
• These developments position Canamera to capitalize on growing demand for secure, strategic sources of critical minerals

Rare earth elements have become indispensable to the technologies powering the global economy, from electric vehicles and wind turbines to advanced defense systems and consumer electronics. Yet despite their strategic importance, global supply chains remain heavily concentrated, with China accounting for more than 60% of rare earth mining and roughly 90% of processing capacity. As geopolitical tensions and export restrictions reshape global trade, governments and manufacturers are increasingly seeking reliable alternative sources of these critical materials (ibn.fm/7Shls).

Brazil is emerging as one of the most promising alternatives.

With favorable geology, well-established mining expertise, supportive government policies, and growing exploration activity, Brazil has become an increasingly attractive destination for companies developing rare earth resources outside China’s sphere of influence. Among those positioning themselves to benefit from this trend is Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF), a critical minerals exploration company advancing a growing portfolio of rare earth projects in Brazil and across the Americas (ibn.fm/vtoAW).

The company’s latest milestone came with the commencement of exploration at its São Sepé Rare Earth Project in Rio Grande do Sul. Historical exploration identified three high-priority target areas (Erica, Sara and Maya) where soil sampling returned encouraging Total Rare Earth Oxide (“TREO”) values along with anomalous concentrations of the valuable heavy rare earth elements dysprosium and terbium.

Dysprosium and terbium play a critical role in manufacturing high-performance permanent magnets used in electric vehicles, offshore wind turbines, robotics, aerospace systems and advanced defense technologies.

To advance the project, Canamera recently launched an approximately 500-meter auger-drilling program designed to evaluate the grade and lateral continuity of potential ionic adsorption clay-hosted mineralization. Ionic clay deposits have attracted significant industry attention because they can often offer lower-cost extraction methods compared to conventional hard rock rare earth deposits while yielding many of the high-value heavy rare earth elements essential to next-generation technologies.

Importantly, the geological setting at São Sepé shares notable similarities with Brazil’s Serra Verde deposit, one of the world’s most significant ionic clay rare earth discoveries outside China. Combined with excellent road infrastructure and favorable logistics, the project offers several characteristics that could support efficient exploration and future development.

São Sepé complements Canamera’s broader Brazilian exploration strategy, alongside its Turvolândia Project, as the company continues assembling a portfolio of district-scale rare earth opportunities in jurisdictions increasingly viewed as strategically important to Western supply chains.

As governments and manufacturers work to diversify critical mineral sourcing amid rising geopolitical uncertainty, companies with exposure to emerging rare earth districts may become increasingly relevant. By advancing multiple Brazilian rare earth assets while targeting the rapidly emerging ionic clay segment, Canamera is positioning itself to benefit from one of the most significant long-term trends in the critical minerals sector. As governments and manufacturers continue seeking secure, diversified supply chains, the company’s growing Brazilian portfolio could become increasingly relevant to the global rare earth market.

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

• The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program.
• The regulatory feedback provides early guidance on the company’s biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform.
• VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies.
• The company’s lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting.
• VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered antibody formats.
• The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has taken another step in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead therapeutic program. The announcement, released on July 20, signals progress as the biotechnology company prepares its most advanced BiTAC(R)-TCE candidate for future clinical development (https://ibn.fm/zBiDU).

Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability and study design.

According to VERAXA, discussions with the PEI focused on the biological mechanism underlying its dual-targeting BiTAC(R)-TCE platform together with its proposed pharmacokinetic strategy and planned non-clinical safety assessments. The company said the feedback indicated that regulators understood the scientific rationale supporting the technology and the proposed development approach. VERAXA believes this provides greater clarity regarding the path forward while reducing some of the uncertainty typically associated with advancing a novel therapeutic modality.

“Scientific Advice on the first therapeutic candidate based on a novel platform is an important early validation, and the feedback we received is encouraging,” said Christoph Erkel, Ph.D., Vice President, Research & Development of VERAXA. “It indicates that the regulatory authorities understand the biological rationale behind our BiTAC-TCE technology approach and gives us greater clarity on the development path we have proposed. For our new modality, such early alignment is crucial to make sure that we progress as efficiently as possible towards the clinics.”

VERAXA’s lead program is built around its proprietary BiTAC(R)-TCE technology, a conditionally active bispecific T-cell engager designed to recognize two target molecules before activating an immune response against cancer cells.

Traditional T-cell engagers have shown promise in oncology but may also activate immune cells against healthy tissues expressing similar targets. VERAXA’s dual-targeting approach is intended to improve selectivity by attacking cancer cells displaying both target markers while reducing activity against cells expressing only one.

The company’s most advanced BiTAC(R)-TCE candidate generated preclinical data presented during the American Association for Cancer Research (“AACR”) Annual Meeting 2026 in April. According to VERAXA, laboratory and animal studies showed the candidate behaved as intended by selectively targeting cancer cells carrying both biomarkers while sparing cells with only a single target. The company also reported that the program demonstrated efficacy comparable to a more conventional T-cell engager while producing a safety profile that could support an improved therapeutic index if confirmed in future studies.

The latest announcement also reflects continued execution of VERAXA’s broader development strategy. The company is building a diversified oncology pipeline centered on next-generation antibody therapeutics. In addition to its BiTAC(R) platform, VERAXA is developing bispecific antibody-drug conjugates (“ADCs”), additional mono- and bispecific ADC candidates, and other engineered antibody formats designed to address multiple forms of cancer.

The company traces its scientific origins to discoveries made at the European Molecular Biology Laboratory (“EMBL”), where research into antibody engineering helped establish the foundation for its current technology platforms. VERAXA has continued advancing several elements of its development program in recent months. Earlier this month, the company announced progress in cell-line development for its lead BiTAC(R)-TCE candidate, an important manufacturing step intended to support future investigational studies and eventual clinical-scale production.

Cancer immunotherapy remains one of the most active areas of drug development, with researchers seeking therapies capable of improving efficacy while reducing treatment-related toxicity. Bispecific antibodies and T-cell engagers have become an increasingly important area of research because they recruit immune cells directly to cancer cells, potentially improving treatment precision.

VERAXA’s BiTAC(R) approach seeks to build on that concept by introducing conditional activation designed to increase tumor selectivity. The company’s immediate focus remains on completing non-clinical development, validating manufacturing capabilities and preparing regulatory submissions required before clinical testing can begin.

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies.
• Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
• The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover.

Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.

Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the work; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. The prevalence of the disease is also increasing.

The disease attacks the myelin sheath, the protective coating surrounding nerve fibers in the brain and spinal cord. When myelin is damaged, communication between the brain and body breaks down. The result can be numbness, vision problems, mobility impairment, cognitive difficulties and, over time, serious and lasting disability.

Available treatments can slow the progression of the disease and can even reduce relapses, but no existing options have been shown to reliably halt or reverse the underlying nerve damage. Companies are working to change that: The global MS therapeutics market was valued at approximately $27.4 billion in 2024 and is projected to reach $38.6 billion by 2030, a reflection of how large and persistent the unmet clinical need remains.

Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Rather than modulating the immune system, Lucid-MS targets protein arginine deiminase 2 (“PAD2”), an enzyme directly involved in myelin degradation. The goal is to protect and potentially restore the myelin sheath itself, addressing the underlying cause of disability rather than managing symptoms.

In preclinical animal models, Lucid-MS accelerated functional recovery, preserved myelin and reduced damage in MS mouse models. Phase 1 clinical trials in healthy human volunteers confirmed a favorable safety profile, with the drug well tolerated and no significant safety concerns reported. In March 2026, the company submitted an Investigational New Drug application to the U.S. FDA for a phase 2 trial.

In April 2026, the company announced that it had formally submitted an Investigational New Drug application to the U.S. FDA for a phase 2 clinical trial of Lucid-MS in people with multiple sclerosis.

Supporting the phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. The study uses a novel PET imaging tracer, [¹⁸F]3F4AP], developed by researchers at MGH and Harvard Medical School. The tracer is designed to directly visualize demyelinated neurons with intact axons, offering a more precise way to measure myelin damage and repair than any currently available technique. Enrollment in the pilot study recently reached its halfway point, with early imaging data showing a robust signal in acute MS lesions.

Alcohol’s impact on the brain is Quantum BioPharma’s second area of focus. Alcohol is one of the most widely consumed and heavily studied psychoactive substances on the planet, responsible for an estimated 2.6 million deaths annually. Alcohol use impairs cognition, slows reaction times, disrupts physiological function and contributes to an enormous global burden of harm. The science has long held that once alcohol enters the bloodstream, only time can metabolize it, approximately one standard drink per hour. Quantum BioPharma challenged that assumption.

The science has long held that once alcohol enters the bloodstream, only time can metabolize it, approximately one standard drink per hour, as the liver processes alcohol at a largely fixed rate. Quantum BioPharma challenged that assumption.

The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. In a double-blind, randomized, placebo-controlled clinical trial, unbuzzd reduced blood alcohol concentration more than 40% faster than placebo within the first 30 minutes after consumption. Participants also reported statistically significant improvements in alertness, reduced headache severity and fewer symptoms of impairment. No adverse side effects were reported.

Those results were published in the “World Journal of Pharmaceutical and Medical Research” earlier this year. The publication marked a meaningful scientific validation for a product, available online, that now sits at the intersection of consumer wellness and clinical evidence. 

Together, Lucid-MS and unbuzzd reflect a company committed to applying rigorous science where existing solutions have fallen short. Quantum BioPharma is advancing both assets with clinical data, peer-reviewed evidence and regulatory engagement, bringing genuine scientific innovation to two areas where patients have long needed better answers. 

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM